Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Thumbnail
View/Open
Publication Date
2017-08
ICR Author
Author
Bozkurt, MF
Virgolini, I
Balogova, S
Beheshti, M
Rubello, D
Decristoforo, C
Ambrosini, V
Kjaer, A
Delgado-Bolton, R
Kunikowska, J
Oyen, WJG
Chiti, A
Giammarile, F
Fanti, S
Type
Journal Article
Metadata
Show full item record
Abstract
PURPOSE & METHODS: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms. RESULTS & CONCLUSION: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
URL
https://repository.icr.ac.uk/handle/internal/1089
Collections
Version of record
Subject
18F–DOPA
18F–FDG
68Ga-DOTANOC
68Ga-DOTATATE
68Ga-DOTATOC
Foregut-NET
Hindgut-NET
Hyperinsulism in infants
Midgut-NET
Neuroendocrine neoplasms
Neuroendocrine tumours
Paraganglioma
Pet/Ct
Pheochromoacytoma
Thyroid medullary cancer
Dihydroxyphenylalanine
Gallium Radioisotopes
Heterocyclic Compounds, 1-Ring
Humans
Image Interpretation, Computer-Assisted
Neuroendocrine Tumors
Peptides
Positron Emission Tomography Computed Tomography
Practice Guidelines as Topic
Quality Control
Receptors, Somatostatin
Tissue Distribution
Research team
Translational Molecular Imaging
Language
eng
Date accepted
2017-05-09
License start date
2017-08
Citation
Eur J Nucl Med Mol Imaging, 2017, 44 (9), pp. 1588 - 1601